Skip to content

Dynavax to get new FDA review of hep B vaccine

March 1, 2017

Dynavax Technologies Corp. DVAX, +53.33% shares surged 54.4% in afternoon trade Wednesday after the company said the Food and Drug Administration would again review its Hepatitis B vaccine, after the regulator decided not to approve it last fall. Dynavax said it has responded to the additional information requested by the FDA, and that the FDA plans to make the decision by August 10. The surge may also be in part attributable to comments made by President Donald Trump during his first Congressional address late Tuesday, in which he said the FDA’s approval process was “slow and burdensome” and that restraints needed to be removed. Dynavax shares have surged 58.0% over the last three months, compared with a 9.6% rise in the S&P 500 SPX, +1.37%


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: